Cargando…
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
Autores principales: | Hammond, Flora M., Alexander, David N., Cutler, Andrew J., D’Amico, Stephen, Doody, Rachelle S., Sauve, William, Zorowitz, Richard D., Davis, Charles S., Shin, Paul, Ledon, Fred, Yonan, Charles, Formella, Andrea E., Siffert, Joao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010732/ https://www.ncbi.nlm.nih.gov/pubmed/27590297 http://dx.doi.org/10.1186/s12883-016-0679-z |
Ejemplares similares
-
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
por: Hammond, Flora M., et al.
Publicado: (2016) -
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
por: Schoedel, Kerri A, et al.
Publicado: (2014) -
Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect
por: Pioro, Erik P.
Publicado: (2014) -
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
por: Pattee, Gary L., et al.
Publicado: (2014) -
Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup
por: Villeneuve, Yannick, et al.
Publicado: (2020)